
Complete if Known

FISHMAN=19A



of | 3

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Application Number 10/565,161 Filling Date November 30, 2005 First Named Inventor Pnina FISHMAN Confirmation No. 7305 Examiner Name Not Yet Known

Attorney Docket Number

			U.S. PA	TENT DOCUMENTS	•
Examiner nitials*	Cite No.1	Document Number Number-Kind Code ^{2 (M known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
N.C.H	AA	US-2004/ 0167094 A1	08-26-2004	FISHMAN et al.	·
	.AB	US-2004/0137477 A1	07-15-2004	FISHMAN et al.	
7	AC	US-2005/0074451	04-07-2005	YEDNOCK et al.	
	AD	US-2005/0065192	03-24-2005	YEDNOCK et al.	
M-CH	AE	US-2002/0119924	08-29-2002	BENDELE et al.	
		US-			
		us-			
		US-			•
		US-			
		US-			•
		US-		·	
		US-			
		US-			
		US-		•	
		US-			
		us-	••		
		us-			

		FOREIC	ON PATENT DO	CUMENTS		
Examiner		Foreign Patent Number Country Code ³ Number ⁴ Kind Code ³ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages. Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
nitials*	No.1				Acievalit i gules Appear	Ľ.
MC.H	AF	AU 200051825 A1	10-26-2000	FELDMANN et al.		_
						-
•					•	
			w			L
						L
						-
		A-A				_

Signature	Date Considered	ı	120108
-----------	--------------------	---	--------

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspio.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 4 Applicant is to place a check mark here If English language Translation is attached.

Complete if Known Substitute for form 1449A/PTO 10/565,161 Application Number INFORMATION DISCLOSURE November 30, 2005 Filing Date STATEMENT BY APPLICANT First Named Inventor Pnina FISHMAN 7305 Group Art Unit Not Yet Known (use as many sheets as necessary) Examiner Name FISHMAN=19A Attorney Docket Number Sheet 2 of 3

		NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION						
		Include name of the author (in CAPITAL, LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
		FISHMAN et al., Evidence for Involvement of Wnt Signaling Pathway in IB-MECA Mediated Suppression of Melanoma Cells; Oncogene, Vol. 21, pp.4060–4064 (2002)						
	АН	FISHMAN et al., Targeting the A3 Adenosine Receptor for Cancer Therapy: Inhibition of Prostate Carcinoma Cell Growth by A3AR Agonist; Anticancer Research Vol. 23: pp. 2077-2083 (2003)						
	Al	MADI et al., A3 Adenosine Receptor Activation in Melanoma Cells, Association Between Receptor Fate and Tumor Growth Inhibition; The Journal of Biological Chemistry, Vol. 278, No. 43, pp.42121-42130, October 24, 2003 ·						
	AJ	OHANA et al., Inhibition of Primary Colon Carcinoma Growth and Liver Metastasis by the A3 Adenosine Receptor Agonist CF101; British Journal of Cancer, Vol. 89, pp. 1552-1558 (2003) XP-002332046						
	AK	FISHMAN et al., An Agonist to the A3 Adenosine Receptor Inhibits Colon Carcinoma Growth in Mice Via Modulation of GSK-3β and NF-κΒ; Oncogene Vol. 23, pp.2465-2471 (2004)						
		SZABO et al., Suppression of Macrophage Inflammatory Protein (MIP)-1a Production and Collagen-Induced Arthritis by Adenosine Receptor Agonists; British Journal of Pharmacology, Vol. 125, pp. 379-387 (1998)						
	АМ	MABLEY et al., The Adenosine A3 Receptor Agonist, N6-(3-lodobenzyl)-Adenosine-5'-N-Methyluronamide, is Protective in Two Murine Models of Colitis; European Journal of Pharmacology, Vol. 466, pp. 323-329, 2003						
	AN	BAHARAV et al., Antiinflammatory Effect of A3 Adenosine Receptor Agonists in Murine Autoimmune Arthritis Models, Journal of Rheumatology, Vol. 32; No. 3, pp. 469-76, 2005						
	AO	MONTESINTOS et al., Adenosine A2A or A3 Receptors are Required for Inhibition of Inflammation by Methotrexate and Its Analog MX-68; Arthritis & Rheumatism, Vol. 48, No.1, pp.240-247, January 2003.						
	AP	MADI et al., The A3 Adenosine Receptor Is Highly Expressed in Tumor Versus Normal Cells: Potential Target for Tumor Growth Inhibition; Clinical Cancer Research, Vol. 10, pp. 4472-4479, July 1, 2004						
	AQ	GESSI et al., Elevated Expression of A3 Adenosine Receptors in Human Colorectal Cancer is Reflected in Peripheral Blood Cells; Clinical Cancer Research, Vol.10, 5895-5901, September 1, 2004						
MOT		CHAN et al., Molecular Action of Methotrexate in Inflammatory Diseases; Arthritis Research. Vol. 4, No. 4; 4, pp. 266-273, 2002.						

	AND DESCRIPTION OF THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NAMED I		
Examiner		Date	
Signature		Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute	for form 1449A/PT0)		Complete if Known		
0000				Application Number	10/565,161	
INFO	RMATIO	N DISC	CLOSURE	Filing Date	November 30, 2005	
STA	TEMENT	RY AP	Filing Date November 30, 2005 PLICANT First Named Inventor Pnina FISHMAN Group Art Unit 7305			
0.7.		EMENT BY APPLICANT	Group Art Unit	7305		
(use as many sheets as necessary)			ecessary)	Examiner Name	Not Yet Known	
Sheet	2	of	3	Attorney Docket Number	FISHMAN=19A	

		NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION				
Examiner Cite Initials' No. Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (b magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or published						
nct	AS	ALETAHA et al., The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses, Rheumatology, Vol. 41, pp. 1367-1374, 2002.				
	AT	MABLEY et al., The A3 adenosine egonist, IB-MECA, protects against the development of arthritis and reverses established arthritis, Experimental Biology 2002: Meeting Abstracts, Section 759.5, page A1044, XP008060305.				
	AU	BAHARAV et al., The effect of adenosine and the A3 adenosine receptor against IB-MECA on joint inflammation and autoimmune diseases models, Abstracts of the Oncology-Molecular Medicine Congress, Section 499, page S104 XP009026428.				
M-C-H		D. KRAUS, Long-term combination therapy of meumatoid arthritis: Methotrexate and parenteral gold, Zeitschrift fuer Rheumatology, Vol. 57, No. 1, pp. 37-40, February 1998 (see tables 1-7).				
			_			

Examiner Signature Date Considered 1/10/08

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.